文献速递癫痫

婴儿不明原因癫痫快速基因组测序无诊断后综合再分析诊断率

Diagnostic Yield of Comprehensive Reanalysis After Nondiagnostic Short-Read Genome Sequencing in Infants With Unexplained Epilepsy.
PubMed 文献 · Neurology · 2026-02-13

该队列研究纳入176例临床快速基因组测序无诊断的不明原因癫痫婴儿,中位年龄642天,进行综合基因组再分析,诊断率为5.1%(9/176),使总体诊断率从43.6%升至46.5%,所有新诊断均有临床实用性。

要点

  • 无诊断快速基因组测序后综合再分析诊断率为5.1%。
  • 再分析使总体诊断率从43.6%提高至46.5%。
  • 新诊断涉及未报告变异及新证据支持的意义不明变异。

核心结论

  • 对无诊断快速基因组测序的不明原因癫痫婴儿,综合再分析有临床实用价值。

研究设计与样本

  • 队列研究纳入4个儿科转诊中心2021年9月至2024年3月招募的不明原因癫痫或复杂热性惊厥婴儿。
  • 对176例初始临床快速基因组测序无诊断的婴儿进行综合再分析,中位年龄642天。

主要发现

  • 再分析诊断率为5.1%(9/176,95% CI 2.4%-9.5%)。
  • 总体诊断率从43.6%(136/312,95% CI 38.0%-49.3%)升至46.5%(145/312,95% CI 40.8%-52.2%)。
  • 新诊断中6例为临床实验室未报告的变异,3例为先前报告的意义不明变异获新证据。
  • 所有诊断均有临床实用性。

关键数值与推荐

  • 再分析诊断率定义为再分析获得遗传诊断的婴儿百分比。

临床怎么用

  • 支持在无诊断基因组测序后1-2年内将再分析纳入不明原因癫痫患儿的常规临床照护。
  • 支持扩展临床认证基因组测序以包括复杂和非编码变异检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The highest incidence of epilepsy in childhood occurs in the first year of life. Infantile epilepsies are associated with substantial morbidity and mortality. Although most are presumed to have genetic etiologies, many infants with nonacquired epilepsy remain genetically unsolved after clinical genome sequencing. The yield of reanalysis after nondiagnostic genome sequencing in this population is unknown. We aimed to determine the diagnostic yield of comprehensive reanalysis after nondiagnostic genome sequencing in infants with unexplained epilepsy. METHODS: This cohort study included infants with unexplained epilepsy or complex febrile seizures who were recruited from 4 pediatric referral centers from September 2021 to March 2024 and had nondiagnostic clinical rapid genome sequencing. We performed comprehensive reanalysis of genome sequencing data from infants and available biological parents using multiple bioinformatics pipelines through July 2025 and clinically confirmed reanalysis findings. The primary outcome was diagnostic yield of genome sequencing reanalysis, defined as the percentage of infants who received genetic diagnoses from reanalysis. The secondary outcome was clinical utility of reanalysis findings. RESULTS: From an initial cohort of 312 infants with unexplained epilepsy who underwent clinical rapid genome sequencing, we performed comprehensive genome reanalysis in 176 infants with initially nondiagnostic results at a median age of 642 days, including 63 female patients (36%) and 30 (17%) with neonatal-onset seizures. The diagnostic yield of reanalysis was 5.1% (9/176, 95% CI 2.4%-9.5%), increasing the overall yield from 43.6% (136/312, 95% CI 38.0%-49.3%) to 46.5% (145/312, 95% CI 40.8%-52.2%). Of the new diagnoses, 6 involved variants not reported by clinical laboratories (2 single nucleotide variants, 2 structural variants, 1 tandem repeat expansion, 1 mosaic variant) and 3 involved previously reported variants of uncertain significance with new evidence. All diagnoses had clinical utility. DISCUSSION: Comprehensive reanalysis after nondiagnostic rapid genome sequencing has utility for infants with unexplained epilepsy. Our findings support implementation of reanalysis within 1-2 years after nondiagnostic genomic sequencing into routine clinical care of children with unexplained epilepsy and the expansion of clinically accredited genomic sequencing to include complex and noncoding variant detection.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nguyen JNH, Lachgar-Ruiz M, Higginbotham EJ, et al. Diagnostic Yield of Comprehensive Reanalysis After Nondiagnostic Short-Read Genome Sequencing in Infants With Unexplained Epilepsy. Neurology. 2026. PMID: 41687048. doi:10.1212/WNL.0000000000214645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。